Research Roundup

light bulb with gears

Debbie Rigby takes a look at the latest in research news

Association of long-term opioid therapy with functional status, adverse outcomes, and mortality among patients with polyneuropathy

In this population-based cohort study (n=1993) long-term opioid therapy among patients with polyneuropathy appears to increase the risk of adverse outcomes without benefiting functional status. Those receiving long-term opioid therapy (>90 days) were significantly more likely to be diagnosed with depression, opioid dependence, or opioid overdose than those receiving shorter durations of opioid therapy.

JAMA Neurol. Published online May 22, 2017.

Medscape summary


Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis

A 800 mg/day pharmaceutical-grade chondroitin sulfate has been shown to be superior to placebo and similar to celecoxib 200mg daily in reducing pain and improving function over 6 months in symptomatic knee osteoarthritis (OA) patients in prospective trial.

Ann Rheum Dis 2017;0:1–7. doi:10.1136/annrheumdis-2016-210860.


Chocolate intake and risk of clinically apparent atrial fibrillation

A Danish cohort study (26 400 men and 29 102 women aged 50–64 years), has shown that  the rate of AF was lower for people consuming 1–3 servings/month (hazard ratio (HR) 0.90), 1 serving/week (HR 0.83), 2–6 servings/week (HR 0.80) and ≥1 servings/day (HR 0.84), compared with chocolate intake less than once per month, with similar results for men and women.

Heart 2017;0:1–5.


Primary Prevention With Statin Therapy in the Elderly

A meta-analysis of age-specific outcome data from 2 recent primary prevention statin trials, JUPITER (Justification for Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) and HOPE-3 (Heart Outcomes Prevention Evaluation) support the use of statins in primary prevention among those ≥70 years of age. The benefit in people aged 80 years and older should be weighed against the potential for a modest impact on longevity.

Circulation. 2017;135:1979-1981

Previous Deadly heatwave warning
Next Forum: I'm a doctor, but don't have my script pad

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.

1 Comment

  1. Catherine De Jonge

    Very Interested to hear about of the trial with the Chondroitin sulphate and celecoxib. Would there be any Chondroitin containing products available in Australia containing the pharmaceutical-grade 4&6 isomers as mentioned. Have been asking companies today and not have much luck sourcing.

Leave a reply